Molecule News and Research

RSS

Autism Speaks announces 47 new ASD research grants

Autism Speaks, the world's largest autism science and advocacy organization, today announced the awarding of 47 new research grants totaling $13,242,279 in funding over the next three years.

22 Dec 2011

Researchers discover how normal cells in tumors can drive cancer growth

•A new study published in the journal Nature Cell Biology has discovered how normal cells in tumors can fuel tumor growth.

22 Dec 2011

Bacteria use host proteins to build camouflaged homes inside healthy cells

Bacteria are able to build camouflaged homes for themselves inside healthy cells - and cause disease - by manipulating a natural cellular process.

21 Dec 2011

GSK, ProteoTech enter R&D agreement to develop new Parkinson's therapeutics

ProteoTech, Inc., a privately held biotechnology company, has entered into a drug development agreement with GlaxoSmithKline (China) R&D Company Limited (GSK) to collaborate on ProteoTech's small molecule technology platform against misfolded proteins to specifically advance work on its alpha-synuclein therapeutic program for the treatment of Parkinson's disease and other synucleinopathies.

21 Dec 2011

Takeda enters agreement to acquire Intellikine

Takeda Pharmaceutical Company Limited and Intellikine, Inc. today announced that Takeda America Holdings, Inc., a wholly-owned subsidiary of Takeda, and Intellikine, a privately-held company focused on the discovery and development of innovative, small molecule drugs, have entered into an agreement for Takeda America Holdings to acquire Intellikine by cash.

21 Dec 2011

Dieting and the youth of the brain may be linked: Study

Italian scientists have found that the mind can be kept young by eating less. They have discovered the molecular process by which a strict diet may save the brain from the ravages of age.

20 Dec 2011

CREB1 molecule activates genes linked to brain longevity

Overeating may cause brain aging while eating less turns on a molecule that helps the brain stay young.

20 Dec 2011

Lostartan can reduce cigarette smoke-induced lung injury

Chronic obstructive pulmonary disease (COPD) is among the most common causes of death in the US. It is a smoking-related disease for which there are currently no disease-altering therapies. However, hope that one could be developed is now provided by the work of Enid Neptune and colleagues, at Johns Hopkins University, Baltimore, in a mouse model of lung disease caused by exposure to cigarette smoke.

20 Dec 2011

Phase I clinical study of Selexys SelG1 for sickle cell disease completed

Selexys Pharmaceuticals announced today that it has completed a Phase I clinical study of its lead compound SelG1, an antibody specific for the pro-inflammatory cell adhesion molecule P-selectin.

19 Dec 2011

Newgen acquires novel oncology development programs from Kanion

NewGen Therapeutics, Inc. today announced the acquisition of three novel oncology development programs from Kanion USA, Inc. and Kanion Pharmaceutical Co., Ltd..

19 Dec 2011

Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia

Alkermes plc today announced the initiation of a phase 3 clinical trial of ALKS 9070 for the treatment of schizophrenia. ALKS 9070, a proprietary Alkermes molecule, is designed to provide patients with once-monthly dosing of a medication that, once in the body, converts into aripiprazole, a molecule that is commercially available under the name ABILIFY for the treatment of a number of central nervous system disorders.

19 Dec 2011

Researchers discover miR-520 blocks cancer-promoting signaling pathway

MicroRNAs or miRNAs are tiny RNA molecules that have only about 20 nucleotides and do not code for proteins. They regulate many important processes in cells by binding to target messenger RNAs - the instructions for protein production -, thus blocking production of the respective protein. In cancer, the production of some miRNAs is often reduced or amplified. This particularly affects miRNAs that regulate the activity of cancer-promoting genes.

17 Dec 2011

Scientists devise a way to reduce side effects of lung cancer therapy

Scientists may have a way to double the efficacy and reduce the side effects of radiation therapy.

17 Dec 2011

Wistar to develop new drug against EBV-associated cancers

The Wistar Institute today announced that it has signed a funding agreement with the Wellcome Trust, a United Kingdom-based charity, to support the development of a new drug to treat cancers associated with Epstein-Barr virus.

16 Dec 2011

Scientists uncover critical genetic mutation in patients with MDS

Scientists have uncovered a critical genetic mutation in some patients with myelodysplastic syndromes - a group of blood cancers that can progress to a fatal form of leukemia.

16 Dec 2011

New drug candidate may halt mental decline of Alzheimer's

A new drug candidate may be the first capable of halting the devastating mental decline of Alzheimer's disease, based on the findings of a study published today in PLoS one.

15 Dec 2011

Researchers identify genetic factors responsible for neurons in the thalamus

The thalamus is the central translator in the brain: Specialized nerve cells (neurons) receive information from the sensory organs, process it, and transmit it deep into the brain. Researchers from the Institute of Toxicology and Genetics (ITG) of KIT have now identified the genetic factors Lhx2 and Lhx9 responsible for the development of these neurons.

15 Dec 2011

Researchers discover novel viral oncogenesis mechanism

Human tumor viruses contribute to 15-20% of human cancers worldwide. Kaposi's sarcoma herpesvirus (KSHV) is an etiological agent for Kaposi's sarcoma (KS) and two other rare lymphoproliferative malignancies. KS is the most common cancer in HIV-infected untreated individuals and remains a primary cause of cancer deaths in many subequatorial African countries as a result of the AIDS pandemic.

15 Dec 2011

Fresh cells can pep talk immune cells exhausted by HIV or hepatitis C

Chronic infections by viruses such as HIV or hepatitis C eventually take hold because they wear the immune system out, a phenomenon immunologists describe as exhaustion.

14 Dec 2011

Chemical disruption to key interaction shown to limit metastasis in test mice

Finding ways to counteract or disrupt the invasive nature of cancer cells, called "metastasis," has been a long-term goal of cancer researchers. Now, researchers at Moffitt Cancer Center in Tampa, Fla., have identified an interactive pathway that regulates metastases in some cancers that may be vulnerable to chemical targeting in order to prevent cancer cell proliferation and tumor growth.

14 Dec 2011